Ryan J. Watts - 20 Apr 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
20 Apr 2023
Transactions value $
-$611,720
Form type
4
Filing time
24 Apr 2023, 19:10:38 UTC
Previous filing
15 Feb 2023
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $136 +200 +0.01% $0.68* 2,240,113 20 Apr 2023 See footnote F1
transaction DNLI Common Stock Sale -$5,000 -200 -0.01% $25 2,239,913 20 Apr 2023 See footnote F1, F2
transaction DNLI Common Stock Options Exercise $16,864 +24,800 +1.11% $0.68* 2,264,713 21 Apr 2023 See footnote F1
transaction DNLI Common Stock Sale -$623,720 -24,800 -1.1% $25.15 2,239,913 21 Apr 2023 See footnote F1, F2, F3
holding DNLI Common Stock 188,437 20 Apr 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -200 -0.02% $0 1,195,417 20 Apr 2023 Common Stock 200 $0.68 Direct F5
transaction DNLI Stock Option (right to buy) Options Exercise $0 -24,800 -2.07% $0 1,170,617 21 Apr 2023 Common Stock 24,800 $0.68 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F2 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023.
F3 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.36 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 Includes 188,437 RSUs.
F5 The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the sharessubject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.